Therapeutics News and Research

RSS

Atypical mutation offers clues to personalized pancreatic cancer treatment

A new study led by Aaron Hobbs, Ph.D., and Rachel Burge, Ph.D., at MUSC Hollings Cancer Center, reveals why a specific gene mutation behaves differently from other variants.

20 Jan 2026

ELRIG announces Drs Stephen Ward and Annarita Miccio as keynote speakers for Cell and Gene Therapy 2026

ELRIG, a not-for-profit, volunteer-led organization dedicated to the global drug discovery community, today announced the keynote speakers for Cell and Gene Therapy 2026. Drs Stephen Ward (Cell and Gene Therapy Catapult) and Annarita Miccio (Imagine Institute) will lead the inaugural two-day event taking place at Hinxton Hall in Cambridge, UK from 9-10 March.

20 Jan 2026

Accelerating kinase drug discovery with validated kinase activity assay kits

The development of new therapeutics targeting protein kinases is crucial in the fight against diseases like cancer.

From Eurofins Discovery 20 Jan 2026

Interferon response key to fighting rhinovirus infections in nasal passages

When a rhinovirus, the most frequent cause of the common cold, infects the lining of our nasal passages, our cells work together to fight the virus by triggering an arsenal of antiviral defenses.

19 Jan 2026

Web-based cytometry atlas reveals immune signatures across pancreatic cancer treatments

Oncologists have achieved some immune system responses in patients with pancreatic cancers using various combinations of vaccines and immune checkpoint inhibitor drugs, but it's not always clear which therapy is inducing what type of response.

16 Jan 2026

New oral drug safely lowers triglycerides and other blood lipids in Phase 1 trial

In a Phase 1 clinical study, researchers led by EPFL and their partners report that a new liver- and gut-targeted oral drug can safely lower triglycerides and other blood lipids.

16 Jan 2026

Bacterial metabolite enhances immune checkpoint therapy against lung cancer

UF Health Cancer Institute researchers have discovered a small compound produced naturally by gut bacteria that doubled the response to lung cancer immunotherapy treatment in mice and can now be made into a drug for testing in humans.

14 Jan 2026

Age-tailored therapies needed for treating the young and old with sepsis

Dealing with an infection isn't as straightforward as simply killing the pathogen. The body also needs to carefully steer and monitor its immune response to prevent collateral damage.

14 Jan 2026

Novel antibody shows promise in overcoming resistance to cancer immunotherapy

According to a Phase I study led by researchers at The University of Texas MD Anderson Cancer Center, published today in Nature Medicine, the novel monoclonal antibody linavonkibart demonstrated the potential to overcome treatment resistance to anti-PD-1 immune checkpoint inhibitors in multiple cancer types.

13 Jan 2026

Preclinical study reveals potential new treatment for severe liver fibrosis

Researchers at McMaster University are leading preclinical studies into a novel drug candidate developed by Espervita Therapeutics that has the potential to prevent and reverse liver fibrosis - a dangerous, disease-induced build-up of scar tissue in the liver that often leads to cancer.

13 Jan 2026

New publication describes the chemical journey of non-hormonal male birth control pill

A newly published manuscript authored by Dr. Gunda Georg, YourChoice Therapeutics and Columbia University Medical Center describes the chemical journey of YCT-529, a non-hormonal male birth control pill, and the promising molecular science behind it.

12 Jan 2026

Resistance to rezatapopt: New TP53 mutations identified in cancer patients

Mutations in the tumor suppressor TP53 are a common cause of cancer, making the altered protein an attractive target for therapeutics.

12 Jan 2026

Personalized cancer therapy significantly enhances treatment success

Researchers at University of California San Diego School of Medicine have led the first clinical trial in the world to show that cancer drug treatments can be safely and effectively personalized based on the unique DNA of a patient's tumor.

12 Jan 2026

George Mason trial: New pill aims to sustain weight loss after GLP-1s

GLP-1 medications like Ozempic and Wegovy have transformed obesity treatment, but maintaining weight loss after the medications stop remains a challenge.

9 Jan 2026

Single-cell analysis illuminates myeloma immune landscape

Scientists at the Icahn School of Medicine at Mount Sinai, in partnership with the Multiple Myeloma Research Foundation (MMRF) and in collaboration with leading institutions across the country, have helped generate the largest single-cell immune cell atlas of the bone marrow in patients with multiple myeloma, a blood cancer that, while treatable, remains incurable.

9 Jan 2026

UCLA awarded major state funding to advance comprehensive cannabis research

UCLA has received four grants totaling $7.3 million from the California Department of Cannabis Control (DCC) to support research on a broad range of topics, from the therapeutic potential of cannabinoids to the cardiovascular risks of cannabis use and strategies for addressing California's unregulated cannabis market.

8 Jan 2026

Individualized drug combinations improve cancer treatment outcomes

8 Jan 2026

UBC researchers crack code to grow helper t cells from stem cells

For the first time, researchers at the University of British Columbia have demonstrated how to reliably produce an important type of human immune cell-known as helper T cells-from stem cells in a controlled laboratory setting.

8 Jan 2026

CIRM awards $7.4 million to advance stem cell-based gene therapy for Friedreich's ataxia

The California Institute for Regenerative Medicine (CIRM) has awarded $7.4 million to support a University of California San Diego team developing a first-of-its-kind stem cell-based gene therapy for Friedreich's ataxia, a rare inherited neurodegenerative disease that causes progressive loss of coordination, muscle strength, heart function and overall mobility.

8 Jan 2026

Specific gut bacteria found to drive alcohol production in patients with auto-brewery syndrome

Researchers at University of California San Diego, Mass General Brigham, and their colleagues have identified specific gut bacteria and metabolic pathways that drive alcohol production in patients with auto-brewery syndrome (ABS).

8 Jan 2026